Branford, S., Cortés, J., Takahashi, N., Larson, R., Issa, G., Bombaci, F., Wang, J., Kim, D., Kim, D., Mayer, J., Goh, Y. T., Coutre, P. L., Kim, I., Etienne, G., Kapoor, S., Jinwal, R., Malek, K., Sarac, A., Bruederle, A., Serrano-Fernandez, P., Milanez-Almeida, P., Hochhaus, A., Hughes, T. (2025). Distinct patterns of mutant ASXL1 over time and their implications for treatment failure (TF) and BCR::ABL1 mutation development in newly diagnosed patients with chronic myeloid leukemia in chronic phase (CML-CP) treated with asciminib (ASC) vs investigator-selected tyrosine kinase inhibitors (IS-TKI) in the ASC4FIRST study. Blood. https://doi.org/10.1182/blood-2025-73